EUVIMEDOpdag EUVIMED
Crossref

Tyrosine kinase 2 inhibition by GL‐V9 treats psoriasiform dermatitis via macrophage‐helper T‐cell modulation

Leyi Chen, Haiyan Tu, Xiaohe Xu, Xiangzheng Li, Shaowen Liu, Rongzhuo Long, He Huang, Qinglong Guo, Xu Chen, Lei Qiang, Yuan He

British Journal of Pharmacology · 2026

DOI: 10.1111/bph.70603 ↗

At a glance

Journal article in British Journal of Pharmacology, 2026. Written by Leyi Chen and 10 co-authors. Institution: School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China. Major MEDLINE topics: TYK2 Kinase, Psoriasis, Macrophages, Protein Kinase Inhibitors. 113 references. Funded by: Chongqing Science and Technology Development Foundation, Postgraduate Research & Practice Innovation Program of Jiangsu Province, Fundamental Research Funds for the Central Universities.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Psoriasis (PsO) is a chronic T lymphocyte‐mediated inflammatory disease arising on a polygenic background. GL‐V9, a structurally optimized flavonoid with reported anti‐inflammatory and anti‐fibrotic activities, was investigated as a potential therapeutic agent for PsO. Experimental Approach The therapeutic and relapse‐preventive effects of GL‐V9 were evaluated in multiple murine models of psoriasiform inflammation. To define its immunomodulatory actions, we established distinct immune‐cell polarization models, including macrophage and T helper cell models, and assessed inflammatory mediator production, immune‐cell polarization and intercellular communication within psoriatic lesions. Mechanistic studies further examined the interaction between GL‐V9 and tyrosine kinase 2 (TYK2), and the functional relevance of TYK2 using siTYK2‐mediated knockdown in bone marrow‐derived macrophages and THP‐1 cells. Key Results GL‐V9 effectively alleviated established psoriasiform dermatitis and reduced disease relapse. Mechanistically, preliminary evidence indicated that GL‐V9 binds to the pseudokinase domain of TYK2 and suppresses JAK/STAT activation, thereby reducing the production of pro‐inflammatory cytokines and chemokines. In M1 macrophages and T helper 1 (Th1) cells, GL‐V9 disrupted TYK2‐dependent signalling, altered pathogenic polarization states and weakened inflammatory communication with neighbouring immune cells, collectively restoring a more balanced immune microenvironment. Conclusions and Implications GL‐V9 ameliorates PsO by targeting TYK2–STAT signalling and reshaping macrophage–T helper cell‐driven inflammation. These findings support GL‐V9 as a promising therapeutic candidate for PsO and other TYK2‐mediated inflammatory diseases.

Subjects

MeSH terms (MEDLINE)

TYK2 KinasePsoriasisMacrophagesProtein Kinase InhibitorsT-Lymphocytes, Helper-InducerFlavonoidsDermatitisAnimalsHumansMiceMice, Inbred C57BLFemaleTyrosine Kinase InhibitorsDisease Models, Animal

Author keywords

JAK–STATTYK2TYK2‐STATflavonoidmacrophagepsoriasis

Substances

TYK2 KinaseProtein Kinase InhibitorsFlavonoidsTyrosine Kinase InhibitorsTyk2 protein, mouse

Authors and institutions

  • School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Institute of Chinese Medical Sciences and State Key Laboratory of Mechanism and Quality of Chinese Medicine, University of Macau, Avenida da Universidade, Taipa, Macau.
  • Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Avenida da Universidade, Taipa, Macau.
  • State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, China.
  • Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China.

Funding

  • Chongqing Science and Technology Development Foundation
  • Postgraduate Research & Practice Innovation Program of Jiangsu Province
  • Fundamental Research Funds for the Central Universities

Cite

APA

Chen, L., Tu, H., Xu, X., Li, X., Liu, S., Long, R., Huang, H., Guo, Q., Chen, X., Qiang, L., & He, Y. (2026). Tyrosine kinase 2 inhibition by GL‐V9 treats psoriasiform dermatitis via macrophage‐helper T‐cell modulation. British Journal of Pharmacology. https://doi.org/10.1111/bph.70603

Vancouver

Chen L, Tu H, Xu X, Li X, Liu S, Long R, et al. Tyrosine kinase 2 inhibition by GL‐V9 treats psoriasiform dermatitis via macrophage‐helper T‐cell modulation. British Journal of Pharmacology. 2026. doi:10.1111/bph.70603

BibTeX
@article{Chen2026,
  author = {Chen, Leyi and Tu, Haiyan and Xu, Xiaohe and Li, Xiangzheng and Liu, Shaowen and Long, Rongzhuo and Huang, He and Guo, Qinglong and Chen, Xu and Qiang, Lei and He, Yuan},
  title = {Tyrosine kinase 2 inhibition by GL‐V9 treats psoriasiform dermatitis via macrophage‐helper T‐cell modulation},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.70603}
}
Start for free →